MYF5

Across TCGA pan-cancer cohorts, MYF5 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated MYF5 data layer compared with 15 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher MYF5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYF5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THCA, STAD, and COAD are the cancer types where MYF5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.070	0.896	<.001	18	view →
STAD	DFS	Median	II,III,IV	0.112	0.615	<.001	18	view →
COAD	OS	Median	II,III,IV	0.163	0.859	<.001	18	view →
UCEC	DFS	Median	All	1.000	0.626	.011	12	view →
PRAD	OS	Median	All	0.265	0.884	<.001	8	view →
LGG	OS	Median	All	0.192	0.799	<.001	7	view →
SKCM	OS	Median	All	0.621	0.795	.007	7	view →
BLCA	DFS	Median	III,IV	0.155	0.574	.002	6	view →
SARC	DFS	Median	All	0.175	0.594	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MYF5–THCA (DFS)

Open the THCA breakdown →